Quarterly Result12 May 2026, 05:51 pm
Cohance Lifesciences Approves FY26 Audited Results
AI Summary
Cohance Lifesciences Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board also approved revisions to the authorized Key Managerial Personnel for determining the materiality of events and information disclosures. The meeting, held on May 12, 2026, also included a review of the 'Policy for Determining Material Event or Information'.
Key Highlights
- Audited standalone and consolidated financial results for FY26 approved.
- Revenue from operations for FY26 stood at ₹2,030.50 Cr.
- Net profit for FY26 reported as ₹228.71 Cr.
- Revisions to Key Managerial Personnel authorized for materiality determination approved.
Price Impact
More from SUVENPHAR